Animal & Veterinary
-
Draft Risk Assessment and the Establishment of Resistance Thresholds Workshop
December 9-10, 1999
-
-
-
December 9th Meeting Transcripts
Welcome and Outline of Scope, Purpose and Objectives of Workshop
Dr. Andrew Beaulieu, FDA, Deputy Director, Center for Veterinary MedicineIntroductions
Dr. Stephen Sundlof, FDA, Director, Center for Veterinary MedicineWhat is Risk Assessment, Risk Management and Risk Communication
Wesley Long, Ph.D., FDA, Associate Scientific Director, JIFSANUse of Risk Assessment in Regulatory Decision-Making
Lester Crawford, C.V.M., Ph.D., Georgetown University Director, Center for Food & Nutrition PolicyThe Importance of Risk Communication in the Development of Science-Based Regulatory Requirements
Douglas Powell, Ph.D., University of Guelph, Department of Plant AgricultureAntibiotic Breakpoints: Methods for Determining and Use by Medical Community
Dr. Al Sheldon, FDA, Center for Drug Evaluation ResearchAntibiotic Breakpoints: Methods for Determining and Use by Veterinary Medical Community
Dr. Tom Shryock, Elanco Animal HealthEpidemiology of Campylobacter in Humans
Kirk Smith, D.V.M., Ph.D., Minnesota Department of HealthEpidemiology of Campylobacter in Animals
Dr. Paula J. Fedorka-Cray, US Department of Agriculture Animal Research ServicePresentation of CVM Risk Assessment
Dr. David Vose, Risk ConsultancyMathematical Validity of CVM Risk Assessment
Dr. Tony Cox, Cox AssociatesChallenges in Assessing and Regulating the Risk of Antimicrobial Use
Dr. Stephen Sundlof, FDA, Center for Veterinary MedicineSession 1: Use of Risk Assessment to Evaluate Human Health Impact of Resistant Pathogens
Chair: Wesley Long, Ph.D.Using Risk Assessment to Evaluate the Human Health Impact of Resistant Pathogens
Dr. Scott McEwen, University of Guelph, Ontario Veterinary CollegeGeorgetown Risk Assessment
Dr. Steve Anderson, US Department of Agriculture, FSIS-AAASEMEA Risk Assessment
Dr. Louise Kelly, Veterinary Laboratories Agency, Department of Risk ResearchCVM Risk Assessment: Assumptions and Uncertainties
Dr. Kathy Hollinger and Mary Bartholomew, FDA, Center for Veterinary MedicinePanel Discussions on CVM RA Model Questions/Comments for Panel Public Comment Period
-
-
December 10th Meeting Transcripts
Introduction
Keith Sterner, D.V.M., VMACAssessment of Risk: Food Additives
Alan Rulis, Ph.D., FDA, Center for Food Safety and Applied NutritionAssessment of Risk: Drug Residues
Kevin Greenlees, Ph.D., FDA, Center for Veterinary MedicineAssessment of Risk: Pesticides
Roy Sjoblad, Ph.D., US Environmental Protection Agency Office of Pesticide ProgramsAssessment of Risk: Microbiological Risks
Dick Whiting, Ph.D., U.S. Environmental Protection AgencyAssessment of Risk: Water
Steve Shaub, Ph.D., U.S. Environmental Protection Agency Office of Science and TechnologyAssessment of Risk: Pathogens on Meat
Kenneth Petersen, Ph.D., USDA Food Safety Inspection ServiceHuman Health Impact from Food-borne Disease
Kenneth Petersen, Ph.D. USDA Food Safety Inspection ServiceHuman Health Impact of Resistant Food-borne Disease
J. Glenn Morris, Jr., M.D., University of Maryland Medical School Department of Epidemiology and MedicineInterpreting and Weighing Risk
J. Glenn Morris, Jr., M.D., University of Maryland Medical School Department of Epidemiology and MedicineEvaluating Risk from Resistant Pathogens under FFDCA
Linda Tollefson, D.V.M., FDA Center for Veterinary MedicinePanel Discussion: How Should CVM Evaluate Risk from Resistant Pathogens Questions/Comments to the Panel Assessment of Risk: Contaminants
Dr. Michael Bolger, Center for Food Safety and Applied NutritionPublic Comment Period Setting Thresholds and Next Steps
Dr. Sharon Thompson, FDA Center for Veterinary Medicine
-
-
-
